The US National Cancer Institute Expands Contract with GENEART by USD 0.8M
Complete the form below to unlock access to ALL audio articles.
GENEART AG has announced an extension of the current agreement with the US National Cancer Institute (part of NIH, the American health authorities) by USD 0.8M.
The NIH are therefore increasing the order volume for the production of genes for the "Mammalian Gene Collection (MGC)" to a total of USD 2.7M in 2008.
More than 3,500 genes with an order volume of approximately USD 3.5M were produced by GENEART last year as part of the basic contract.
The National Cancer Institute uses the genes synthesized by GENEART to supplement the Mammalian Gene Collection - a comprehensive collection of genes from mice, rats, and humans, both for basic research and for applied medical research.
The genes that have been produced so far are composed of complex repeat motifs, they are quite large and for most part are rare transcripts. In order to produce the requested highly complex genes efficiently in high throughput, GENEART further advanced its synthesis processes and established new production techniques last year.
